Revenue: As of FY2026 Q2, the actual value is USD 166.46 K.

EPS: As of FY2026 Q2, the actual value is USD -0.27.

EBIT: As of FY2026 Q2, the actual value is USD -3.1 M.

Financial Overview

Net Revenue from Continuing Operations

• For the three months ended June 30, 2026, net revenues from continuing operations were $166,458, compared to $380,797 for the same period in 2025.
• For the six months ended June 30, 2026, net revenues from continuing operations were $330,308, compared to $547,425 for the same period in 2025.

Net Loss

• Cumberland Pharmaceuticals Inc. reported a net loss from continuing operations of - $3.1 million for the second quarter of 2026.
• The total net loss for the second quarter of 2026 was - $4,113,702, compared to a net loss of - $735,206 for the second quarter of 2025.
• For the six months ended June 30, 2026, the total net loss was - $7,561,481, compared to a net income of $512,977 for the same period in 2025.

Operating Loss

• Operating loss for the three months ended June 30, 2026, was - $3,160,461, compared to - $3,119,519 for the same period in 2025.
• Operating loss for the six months ended June 30, 2026, was - $6,092,831, compared to - $5,842,496 for the same period in 2025.

Operating Costs

• Research and development costs for the three months ended June 30, 2026, were $772,162, down from $837,401 in 2025.
• General and administrative costs for the three months ended June 30, 2026, were $2,547,606, down from $2,657,146 in 2025.
• For the six months ended June 30, 2026, research and development costs were $1,538,007, compared to $1,522,188 in 2025.
• For the six months ended June 30, 2026, general and administrative costs were $4,870,980, compared to $4,855,889 in 2025.

Balance Sheet Highlights (as of June 30, 2026)

• Total assets were $62,879,694, a decrease from $76,823,992 at December 31, 2025.
• Cash and cash equivalents totaled $3,862,402, down from $11,444,693 at December 31, 2025.
• Total liabilities were $45,773,246, compared to $52,279,770 at December 31, 2025.
• Total shareholders’ equity was $17,438,013, a decrease from $24,880,322 at December 31, 2025.
• The revolving line of credit - long term was retired, showing - $0 at June 30, 2026, down from $5,240,733 at December 31, 2025.

Cash Flow from Operating Activities

• Net cash provided by operating activities was $559,850 for the six months ended June 30, 2026, compared to $4,720,732 for the same period in 2025.
• Net cash used in investing activities was - $1,991,676 for the six months ended June 30, 2026, compared to - $920,737 for the same period in 2025.
• Net cash used in financing activities was - $6,150,465 for the six months ended June 30, 2026, compared to - $5,676,899 for the same period in 2025.

Strategic Transaction and Special Dividend

• Cumberland Pharmaceuticals Inc. closed a strategic transaction with Apotex Health on July 1, 2026, involving the sale of its portfolio of FDA-approved brands for $100 million in cash, plus an additional $11 million for inventory and transition services.
• The company declared a special cash dividend of $1.50 per share, paid on July 31, 2026, to shareholders of record as of July 23, 2026.

Operational Metrics and Clinical Pipeline

• Following a strategic transaction, Cumberland Pharmaceuticals Inc. will transition into a development-stage biopharmaceutical organization focused on advancing differentiated medicines for rare diseases and unmet medical needs, retaining its development pipeline, including four Phase 2 clinical programs.
• Updated results from the Phase 2 FIGHT DMD clinical trial evaluating ifetroban showed new blood biomarker findings consistent with heart muscle protection.
• A Phase 2 study evaluating ifetroban to inhibit cancer metastasis met its primary objective of assessing safety and feasibility, showing metastatic recurrence in 17% of ifetroban-treated patients compared to 50% in placebo, with no deaths from distant metastatic disease in ifetroban patients compared to 30% in placebo.

Outlook

Cumberland Pharmaceuticals Inc. is positioned to operate as an innovation-focused development-stage biopharmaceutical organization after strengthening its balance sheet and returning capital to shareholders. The company retains significant liquidity and financial flexibility to fund long-term product development efforts and pursue additional strategic opportunities. It plans to advance its pipeline of differentiated product candidates designed to address significant unmet medical needs.